Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

19.32 -0.57 (-2.87%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces CEO Transition
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement 
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces Presentations at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.